{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 974f9da8-060a-4151-9709-78f2d853a5bb --><h2>Changes</h2><!-- end field 974f9da8-060a-4151-9709-78f2d853a5bb -->","summary":null,"htmlStringContent":"<!-- begin item 069c8432-dd42-4f5c-8dee-ad55a9068b15 --><!-- begin field daec612c-302a-4f0a-8645-55a2b3c9fb8c --><p><strong>November 2020 </strong>— minor update. Myoclonus added as an adverse effect of ranolazine in line with updated manufacturer's SPC.</p><p><strong>June 2020 </strong>— minor update. Adverse reactions for diltiazem added in line with updated manufacturer's SPC.</p><p><strong>October 2019</strong> — minor update. The contraindications and cautions section for calcium-channel blockers was updated to clarify that verapamil and diltiazem are contraindicated for people with atrial fibrillation and flutter associated with accessory conducting pathways (e.g. Wolff-Parkinson-White-syndrome).</p><p><strong>January 2018 </strong>— minor update. Revised SPC for Istin (amlodipine) 5 and 10mg tablets. Drug interactions updated as per the revised SPC.</p><p><strong>October 2017 </strong>— minor update. NSAIDs added as a potential drug interaction with nicorandil. </p><p><strong>January to February 2017</strong> — reviewed. A literature search was conducted in January 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.  </p><!-- end field daec612c-302a-4f0a-8645-55a2b3c9fb8c --><!-- end item 069c8432-dd42-4f5c-8dee-ad55a9068b15 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"0a87b39f-6bc6-5ab8-b3ad-fc73e839f6ed","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field abda7754-3965-43c0-9864-3698a13b1251 --><h3>Previous changes</h3><!-- end field abda7754-3965-43c0-9864-3698a13b1251 -->","summary":null,"htmlStringContent":"<!-- begin item 6997eaa5-904c-416f-9cea-c7bcc8ec8c9b --><!-- begin field 4a71c3da-06f0-404c-89ba-d04cc4c9dd24 --><p><strong>December 2016 </strong>— minor updates.</p><ul><li>The adverse effects, contraindications and interactions for isosorbide mononitrate have been updated in line with the manufacturer's Summary of Product Characteristics.</li><li>The contraindications and interactions for verapamil and diltiazem have been updated in line with the manufacturers' Summary of Product Characteristics.</li><li>Sinus arrest, and cardiac arrest (asystole) have been added as possible adverse effects of diltiazem in line with the manufacturers' Summary of Product Characteristics.</li><li>Medicines and Healthcare products Regulatory Agency (MHRA) advice about the risk of ulcer complications with nicorandil has been updated and clarified.</li></ul><p><strong>November 2016 </strong>— minor update. The adverse effects of ranolazine have been updated in line with the manufacturer's Summary of Product Characteristics.</p><p><strong>October 2015 </strong>— minor update. The information on beta blockers in the Prescribing information section, has been re-worded to reflect advice from the manufacturers' Summary of Product Characteristics, in relation to the cautions and contraindications of beta blockers if the person has a form of obstructive airways disease.</p><p><strong>June 2015 </strong>— minor update. Based on updates to the manufacturers' Summaries of Product Characteristics (SPCs):</p><ul><li>Contraindications to the use of ivabradine have been updated to include people younger than 18 years of age.</li><li>Information on the potential drug interaction of diltiazem and amlodipine with grapefruit and grapefruit juice has been added to the topic.</li></ul><p><strong>February 2015 </strong>— minor update. The text has been updated to reflect recently published guidance by the Medicines and Healthcare products Regulatory Agency (MHRA) on ivabradine.</p><p><strong>September 2014 </strong>— minor update. An additional adverse effect for ivabradine has been added.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>January 2013 </strong>— minor update. Removed the black triangle status from ivabradine as this is no longer a black triangle drug.</p><p><strong>January 2012 to April 2012 </strong>— reviewed. This topic has been updated to reflect the National Institute for Health and Care Excellence (NICE) clinical guideline, <em>Management of Stable Angina</em>. Issued in May 2012.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>March 2011 </strong>— minor update. Diagnostic sections and information on referral of suspected angina amended to be consistent with the National Institute for Health and Care Excellence (NICE) guideline <em>Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin</em>.</p><p><strong>October 2010 </strong>— minor update. Text amended to include advice about flying for people with angina, based on the British Heart Foundation (BHF) Factfile, <em>Fitness to fly for passengers with cardiovascular disease</em>, which is derived from the British Cardiovascular Society Working Group's expert guidance. Issued in October 2010.</p><p><strong>January 2010 </strong>— minor update. Ivabradine is now licensed for use in combination with a beta-blocker in people who are inadequately controlled with an optimal beta-blocker dose and whose heart rate is greater than 60 beats per minute. The recommendations regarding people with poor control on existing treatment have been updated. Issued in January 2010.</p><p><strong>April to September 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The anti-anginal drug ivabradine has been added as an alternative to a calcium-channel blocker, a nitrate, or nicorandil in people who cannot take a beta-blocker.</p><p><strong>April 2009 </strong>— minor update. The section on <em>GMS quality indicators </em>in the <em>Goals and outcome measure s</em>ection has been renamed <em>QOF indicators</em>. Issued in May 2009.</p><p><strong>July 2008 </strong>— minor update to the text for nicorandil to reflect recently published drug safety information on nicorandil from the MHRA.</p><p><strong>April to September 2006 </strong>— reviewed. Validated in September 2006 (update validated in December 2006). Issued in January 2007.</p><p><strong>October 2005 </strong>— minor update. Reference made to the CKS topic on <em>Antiplatelet treatment</em>, which outlines gastrointestinal issues that need to be considered in the prescribing of low-dose aspirin for the prevention of cardiovascular events. Issued in November 2005.</p><p><strong>November 2002 </strong>— reviewed and updated to incorporate the Scottish Intercollegiate Guidelines Network (SIGN) guideline on the Management of Stable Angina (2001). Validated in March 2003 and issued in April 2003.</p><p><strong>November 2000 </strong>— updated to incorporate the National Service Framework for Coronary Heart Disease (2000) chapter on angina. Validated in November 2000 and issued in December 2000.</p><p><strong>May 1999 </strong>— reviewed, in particular taking into account the updated North of England evidence-based guidelines on the management of stable angina (unpublished 1999 update).</p><!-- end field 4a71c3da-06f0-404c-89ba-d04cc4c9dd24 --><!-- end item 6997eaa5-904c-416f-9cea-c7bcc8ec8c9b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}